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Abstract
Aims The VEGAS study was conducted to evaluate rep-
resentative data of de novo insulin-treated older patients
with type 2 diabetes in the outpatient setting in Germany.
Methods In this prospective, multicenter, non-interven-
tional observational study, a nationwide written survey was
carried out among practitioners (02/2011–06/2011). Older
patients, aged C70 years, starting de novo insulin therapy,
were documented.
Results Data from 4,858 patients from about 500 centers
(mean age: 78.2 ± 5.4 years; mean glycosylated he-
moglobin [HbA1c]: 70 ± 14.2 mmol/mol [8.6 ± 1.3 %])
were collected. The mean target HbA1c value was
55 ± 6.6 mmol/mol (7.2 ± 0.6 %). 91.1 % of geriatric
patients were multi-morbid. 96.2 % showed at least one
physical or psychological geriatric syndrome. Most of the
patients were notably impaired according to their age.
Conventional insulin therapy and basal-supported oral
therapy were the most frequently planned treatment regi-
mens (39.1 and 31.1 %). Important factors in the selection
of the insulin treatment regimen were an efficient HbA1c
decrease (65.6 %), easy administration (55.7 %), and also a
patient’s ability to self-administer insulin (38.5 %). De
novo insulin treatment increased care requirements
(22.7 %). 22.3 % of the relatives were scheduled to receive
special training. Specific training programs for older pa-
tients with diabetes were planned in only 7.3 % of cases.
Conclusions The data demonstrate the high prevalence of
geriatric syndromes during de novo insulin treatment. In-
dividual therapeutic goals and regimes are based on prac-
ticability, in particular, the receipt of autonomy and the
care requirement. Diabetes education with adapted pro-
grams is currently under-represented. Important factors for
the choice of an insulin treatment regimen were an efficient
HbA1c decrease, easy administration, and a patient’s ability
for self-administration.
Key Points
Observational health study of a real-world cohort of
older (age [70 years), multi-morbid patients with
diabetes mellitus starting on insulin treatment.
The first study to establish the reasons, strategies,
and expectations of the treating general practitioners
in de novo insulin therapy in older patients with
diabetes.
A closer examination of the use of educational
programs for older patients with diabetes and their
carers.
A complete list of the study centers can be found in the supplementary
data online.
Electronic supplementary material The online version of this
article (doi:10.1007/s40801-015-0014-9) contains supplementary
material, which is available to authorized users.
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Introduction
Diabetes mellitus is a global health problem that will grow in
magnitude as a result of worldwide demographic aging [1].
The treatment of older people with diabetes with their age-
related high morbidity and high prevalence of geriatric
syndromes (such as immobility, incontinence, dementia) is a
great medical and economic challenge in present times [2, 3].
Practice guidelines for the management of diabetes in
older people have to consider special conditions such as
multi-morbidity, cognitive and physical impairment, and
the need to evaluate an individual’s goals including life
perspective and quality of life [4].
Two leading associations in Germany, the German
Diabetes Association (Deutsche Diabetes Gesellschaft,
DDG) and the German Geriatric Society, have published
evidence-based guidelines for the diagnosis, treatment, and
follow-up of diabetes in older patients that combined
aspects of diabetology with aspects of clinical geriatric
medicine [5]. These guidelines provide recommendations
for insulin therapy when the individual therapeutic goal
cannot be achieved through diet modification and/or oral
anti-diabetic agents (usually for a glycosylated hemoglobin
[HbA1c] value of [64 mmol/mol [ 8 %]) [5]. Insulin
therapy should ideally begin in conjunction with a struc-
tured treatment and educational program including for
persons of advanced age [5–7]. Furthermore, older people
with diabetes sometimes seem to benefit from the anabolic
effect of insulin by an improvement in strength, mobility,
and, in some cases, cognition [6, 8–10].
Despite a great social interest, data demonstrating the
current healthcare situation of de novo insulin-treated older
people with diabetes in Germany are scarce. Only a small
number of local studies analyzed the healthcare structure in
outpatient or inpatient care facilities [11, 12]. Nationwide
data are only available for a limited and non-representative
number of older persons with type 2 diabetes [13].
This nationwide observational multicenter study was
conducted to evaluate representative data of de novo in-
sulin-treated older persons with type 2 diabetes in an out-
patient setting in Germany. In this context, both the
particular patient population with a focus on geriatric
syndromes and the reasons for individual medical decisions
were analyzed.
Patients and Methods
This prospective, multicenter, open-label, non-interven-
tional observational study was conducted from February to
June 2011 to gain more insight into important factors and
reasons for medical decisions in the first-time insulin
treatment of older persons with type 2 diabetes in Ger-
many. A nationwide written survey via a standardized
questionnaire was carried out among practitioners spe-
cialized in diabetology. There were about 1,150 practi-
tioners specialized in diabetology (‘‘centers’’) in Germany
at that time, according to an official statement of the DDG
[14]. They were invited to participate in the study if they
received scientific field force visits. A representative
number of centers should participate.
Older persons (aged C70 years, experiencing multimor-
bidity and geriatric syndromes) scheduled to receive first-
time insulin therapy were included independently of the in-
sulin preparation used. Geriatric syndromes refers to multi-
factorial health conditions that occur when the accumulated
effects on multiple systems render an older person vul-
nerable to situational changes [15]. We analyzed the geriatric
symptoms: impairment of vision and hearing, fine motor
skills, gait, falls, depression, cognition, and urinary and
bowel continency. A cognitive deficiency or physical im-
pairment (frailty) was attributed clinically by the general
practitioners, multi-morbidity was defined by the presence
of three or more different diagnoses. Persons with the fol-
lowing characteristics were excluded from the analysis:
age\70 years, no documentation of year of birth, or pre-treated
with insulin, or persons with incomplete questionnaires.
Patient characteristics, age-related and anamnestic data,
glycemic metabolism parameters, and details of the de
novo insulin treatment were recorded.
Statistical Analysis
Data analysis was provided by SAS (Version 9.2). Descrip-
tive statistical methods were used. With respect to quanti-
tative variables, the following statistical parameters were
determined: number of valid data, arithmetic mean, standard
deviation, range, and selected quantiles. Qualitative data
were calculated with absolute and relative frequency distri-
butions. Where calculated frequencies referred to a distinct
basic population other than the total patient number of 4,858
(because of different amounts of valid data), the corre-
sponding number is indicated in brackets.
The impact of variables on investigation parameters was
evaluated by a subgroup analysis.
Results
Demographic and Baseline Characteristics
Five hundred and thirty-six centers received 5,398 ques-
tionnaires. Five hundred and twenty-four centers returned
5,171 questionnaires and thereof 5,060 questionnaires were
completed. One hundred and fifty-one were filled in with
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persons born after 1940, 26 lacked years of birth, and 25
had had insulin before. In total, 4,858 persons from about
500 centers were available for evaluation. The centers were
evenly allocated in Germany with regard to areas of high
population density (Supplemental Fig. S1). We did not
look for differences between rural or urban areas because
we did not ask for the residence of the patients. The sex
distribution was almost equal (women: 51.2 %; men:
48.0 %; no data: 0.8 %). Mean age was 78.2 ± 5.4 years,
whereby more than one third of the persons (38.2 %) were
at least 80 years old. Of persons with diabetes (n = 4,804),
45.5 % were obese with a body mass index C30 kg/m2
[16]. Nearly half of the persons had type 2 diabetes for a
minimum of 10 years (48.6 %; mean: 11.0 ± 7.7 years;
n = 4,689). Further patient characteristics and details of
status parameters are given in Table 1.
The vast majority of the 4,858 patients with diabetes
received metformin (77.7 %) and sulfonylurea (53.2 %) as
previous anti-diabetic therapy. Importantly, in 58.2 %
of the metformin-treated patients and in 18.8 % of the
sulfonylurea-treated patients, the previous therapy was
planned to be continued in combination with insulin
(Supplemental Table S1).
Before starting de novo insulin treatment, the mean
HbA1c value was 70 ± 14.2 mmol/mol (8.6 ± 1.3 %). The
mean target HbA1c value that was expected by starting on
insulin therapy was 55 ± 6.6 mmol/mol (7.2 ± 0.6 %)
(Supplemental Table S2).
Characteristics of the Older Patients
Of the 4,858 patients, 81.2 % had at least one geriatric
syndrome. 32.7 % of the persons were over 80 years of
age, 33 % were described as ‘‘frail’’ by their physicians,
32.9 % showed cognitive impairment, and 35.7 % received
poly-pharmacotherapy. In total, 4,424 of the 4,858 geriatric
persons were multi-morbid (91.1 %). The three most fre-
quently documented chronic diseases were heart disease
(71.5 %), cerebrovascular disease (33.6 %), and neuro-
logical disease (30.1 %). Furthermore, 29.9 % of patients
had osteoarthritis, 11.6 % from malignant diseases and
11.5 % from other diseases, such as chronic obstructive
pulmonary disease or arterial hypertension.
Cognitive and physical impairment were documented in
nearly all persons (Fig. 1). 96.2 % of the persons with
diabetes showed at least one geriatric symptom and more
than two thirds (67.5 %) had at least five of the analyzed
geriatric symptoms. Most of the patients were slightly
impaired according to their age. However, 27.6 % of all
persons were severely handicapped in walking and at least
one fall within the last 3 months was reported for almost
45 % of the persons. A cognitive deficit was documented
for more than 70 % of the persons. Almost 80 % of the
persons had reduced hearing. Additionally, depressive
symptoms were reported for 55.2 % and incontinence for
38.4 % of the study population.
Details of the patients’ living conditions, care level, and
care requirements before the first-time insulin treatment are
given in Supplemental Tables S3, S4, and S5.
Diabetic Complications and Creatinine Clearance
82.7 % of all persons had diabetic complications, mostly
from neuropathy (55.1 %), macrovascular complications






Health insurance/health payera [%]
Statutory health insurance 85.1
Private health insurance 6.3
Health insurance for civil servants 0.6
Age [years] (range; median) 78.2 ± 5.4
(71–102; 77)
Body heightb [cm] 167.8 ± 8.9
Body weightc [kg] 84.7 ± 16.1
Abdominal girthd [cm] 104.1 ± 15.1
BMIe [kg/m2] 30.1 ± 5.2
Blood pressuref [systolic/diastolic (mmHg)] 140.4/82.3 ± 16.3/
11.3
Creatinineg [lmol/L] 106.10 ± 35.37
HbA1c
h [mmol/mol (%)] 70 ± 14
(8.6 ± 1.3)
Fasting blood glucosei [mmol/L] 9.3 ± 2.64
Post-prandial blood glucosej [mmol/L] 12.38 ± 3.47




Values are indicated as arithmetic mean ± standard deviation or
relative frequencies, when indicated also as (range; median). In total,
n = 4,858 patients have been documented
BMI body mass index, HBA1c glycosylated hemoglobin
a Multiple answers were possible
b n = 4,809
c n = 4,826
d n = 3,270
e n = 4,804
f n = 4,610/4,592
g n = 4,337
h n = 4,815
i n = 4,614
j n = 4,316
k n = 4,689
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(33.8 %), nephropathy (29.7 %), or retinopathy (28.2 %),
but underestimation was likely owing to barriers to access
to specialists. 19.8 % of all persons had a diabetic foot
syndrome.
Analyzing the creatinine clearance determined by the
Modification of Diet in Renal Disease formula revealed
that 2,055 (42.3 %) of the study population had an esti-
mated glomerular filtration rate\60 mL/min and therefore
a moderate or severe loss of renal function. A severe loss of
renal function was documented in 233 (4.8 %) patients.
Patients with nephropathy had more moderate to severe
renal insufficiency (\60 mL/min: 68 % [983], \30 mL/
min: 11 % [159]; n = 1,445) than the overall patient
population. In 39.4 % of the 3,777 patients who had re-
ceived previous metformin therapy there was an estimated
glomerular filtration rate of \60 mL/min and for 127
(3.4 %) patients it was \30 mL/min. Although metformin
is contraindicated in persons with a creatinine clear-
ance \60 mL/min [5, 17] in Germany, metformin therapy
was planned to be continued during first-time insulin
treatment in 40.8 % of the 1,487 persons with moderate to
severe loss of renal function.
De novo Insulin Treatment
The conventional therapy (CT) was the most frequently
planned treatment regimen (39.1 %), followed by the
basal-supported oral therapy (BOT) (31.1 %) (Fig. 2).
Details on the initial dosages of the different treatment
regimens are given in Supplemental Table S6.
A subgroup analysis revealed that older age (C80 years
vs. \80 years: 45.7 % [n = 1,855] vs. 35.1 % [n = 2,997]),
a higher HbA1c C64 mmol/mol vs.\64 mmol/mol [C8 %
vs. \8 %]: 41.6 % [n = 3,261] vs. 33.7 % [n = 1,548]),
cognitive impairment (yes vs. no: 42.5 % [n = 3,464] vs.
30.5 % [n = 1,337]) or a care level (yes vs. no: 48.6 %
[n = 1,600] vs. 34.4 % [n = 3,200]) was more frequent
under the CT treatment regimen.
The three most important reasons for choosing the
treatment regimen were ‘‘efficient decrease of HbA1c’’
(65.6 %), ‘‘easy administration’’ (55.7 %), and ‘‘targeted
treatment of the fasting blood glucose’’ (44.0 %). Addi-
tionally, ‘‘targeted treatment of post-prandial blood glu-
cose’’ (40.2 %), ‘‘patient can do it by himself’’ (38.5 %),
‘‘enabled through the nursing care’’ (18.9 %), ‘‘flexibility’’
(18.5 %), ‘‘data situation’’ (7.7 %), ‘‘costs’’ (3.0 %), and
‘‘others’’ (4.3 %) were given as further reasons.
More than half of the older patients with diabetes were
treated with human insulin alone (51.5 %) (Fig. 3b). Fur-
thermore, 41.4 % of the persons received insulin analogs
alone. A subgroup analysis showed that older patients (age
C80 years vs. age \80 years: 54.9 % [n = 1,813] vs.
52.1 % [n = 2,895]), with a longer diabetes duration
(C10 years vs. \10 years: 53.2 % [n = 2,211] vs. 52.8 %
[n = 2,335]) and lower HbA1c values before the treatment
change [\64 mmol/mol vs. C64 mmol/mol (\8 vs. C8%):
55.5 % (n = 1,491) vs. 52.2 % (n = 3,177)] more often
received human insulin than the comparative group.
Insulin was administered via a single-use pen in 68.5 %
of all persons (Fig. 3a), and in 70.9 % of persons with
impaired fine motor skills (n = 3,873). The administration
was mostly carried out by the patient (Fig. 3c). Injections
by others were often associated with cognitive impairment
Fig. 1 Cognitive and physical impairment of the geriatric patients
(n = 4,858). Black bars no data; diagonally striped bars not
impaired; white bars slightly impaired appropriate to age; horizon-
tally striped bars severely impaired
Fig. 2 Treatment regimen (n = 4,858); no data from six subjects
(0.1 %). BOT basal-supported oral therapy, CT conventional therapy,
ICT intensive conventional insulin therapy, SIT supplementary insulin
therapy
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of the patient. 47.9 % of persons with cognitive impair-
ment (n = 3,464) did not self-administer.
The de novo insulin treatment increased care require-
ments in 22.7 % of all persons with diabetes. 11.2 % re-
quired nursing care for the first time (Supplemental Table
S5).
Accordingly, increased care requirements after first-time
insulin treatment are required more often in patients aged
80 years and older (C80 years vs. \80 years: 31.1 %
[n = 1,809] vs. 18.6 % [n = 2,909]), with a diabetes du-
ration of at least 10 years (C10 years vs. \10 years:
26.1 % [n = 2,221] vs. 20.8 % [n = 2,336]), with HbA1C
values of C64 mmol/mol (C8 %) C64 mmol/mol
vs.\64 mmol/mol (C8 vs.\8 %): 26.8 % [n = 3,175] vs.
16.2 % [n = 1,502]) or in patients with classification into a
care level (yes vs. no: 49.7 % [n = 1,574] vs. 9.9 %
[n = 3,105]).
Training Programs
A training program was planned for 3,124 (64.3 %) pa-
tients and in 1,085 (22.3 %) patients for their relatives. The
intended training duration was 5.7 ± 5.1 h for older pa-
tients and 4.7 ± 5.1 h for relatives.
The vast majority of patients with cognitive impairment
were also scheduled to attend training programs (57.2 %;
ntotal 3,464). Training programs for relatives and nurses
were planned for only 889 and 624 (25.9 and 18.0 %; ntotal
3,464) of these persons, respectively.
A training program was specified for only 45.7 % of all
patients. In nearly 25 % of all patients, the standard
training course for adults with type 2 diabetes (Central
Institute of the Association of Statutory Health Insurance
Physicians [CI-training course]) was chosen and in ap-
proximately 7 % of all patients the MEDIAS 2 program
(for middle-aged persons with type 2 diabetes) was chosen.
Additionally, a structured diabetes treatment and teaching
program (DTTP) specialized for older multi-morbid per-
sons with diabetes, called the SGS (structured geriatric
DTTP) [7], was chosen for education for 354 persons
(7.3 %), whereas only for 280 patients (8.1 %) with cog-
nitive dysfunction (n = 3,464) an attendance of SGS was
planned. For 436 (9.5 %) of all persons other teaching
programs were mentioned, such as LINDA, a self-man-
agement program for persons with type 1 and type 2 dia-
betes. OveraIl, in most of the questionnaires, no teaching
program was indicated (2,639; 54.3 %).
Discussion
The study data impressively demonstrate a high prevalence
of geriatric syndromes during de novo insulin treatment of
the analyzed patient pool. Persons with diabetes in general
have a high prevalence of geriatric syndromes such as
functional disabilities, depression, falls, urinary inconti-
nence, pain and dementia, correlated to age, diabetes du-
ration, and control of glycemia and hypertension [18, 19].
Physicians underestimated geriatric diagnostic features in
this survey. Although nearly all patients showed at least
one physical or cognitive disorder, physicians described
their patients in only one third of the cases as ‘‘frail’’ or
with ‘‘cognitive deficiency’’. The presence of geriatric
syndromes was not clearly associated with special ap-
proaches as it should be [8, 20, 21]. The underestimation of
geriatric problems including cognitive decline and physical
disability is a common dilemma [22, 23].
Besides the geriatric syndromes at the time of first-in-
sulin treatment, health status was also seriously affected.
VEGAS participants were affected more severely than the
low functioning group with diabetes in AHEAD, a study
demonstrating the impact of diabetes on functional status
and long-term outcomes, despite corresponding age [3].
Fried et al. [24] noted in the context of aged persons with
diabetes that frailty is not synonymous with either co-
morbidity or disability, but comorbidity is an etiologic risk
factor for, and disability is an outcome of frailty. It ac-
counts for the higher direct health costs of diabetes [21].
The most frequent reason for insulin therapy was the
necessary decrease in HbA1c. Mean HbA1c values previous
Fig. 3 Insulin and insulin administration (n = 4,858). a Administra-
tion form. Nine patients used a syringe (0.2 %), three patients
administered via an insulin pump (0.1 %). b Types of insulin.
c Administering patients. Administered by ‘‘others’’: n = 10; 0.2 %
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to the initiation of insulin treatment were considerably
higher than the target value of \64 mmol/mol (\8 %)
recommended by the German Diabetes Association and
German Geriatric Society for older people with diabetes [5,
6]. In contrast, individual therapeutic targets reported by
the participating physicians were in the lower range of
recommended HbA1c for older patients with diabetes [5, 6]
and corresponded most closely with the explicit risk-s-
tratified approach of the current Department of Veterans
Affairs/Department of Defense guidelines [25]. There is
little knowledge about decision-making for targets in
Germany. Therapeutic targets should be established be-
tween doctors and participants against the background of
individual threat according to the disease management
program ‘‘AOK Curaplan Diabetes Mellitus Type 2’’ of the
German public health insurance [26].
All in all, there was a high multi-morbidity in the sample,
most persons with diabetes complications, causing new
troubles in diabetes management. In four out of 10 persons
with a creatinine clearance of\60 mL/min, a continuation of
metformin treatment was planned. This poses a problem, as
metformin is contraindicated in Germany for use in renal
impairment, as it is in hepatic insufficiency, cardiac insuffi-
ciency, and all diseases with a risk of elevated lactate levels
[5, 17]. Either the advantages of metformin therapy seemed
to be of major importance to the GPs or metformin therapy
would be suspended in future.
Important factors of the insulin treatment regimen se-
lection were efficient decrease of HbA1c, easy administra-
tion, but also the ability of the older patient to self-
administer insulin. The request for easy administration and
patient’s independence is reflected in the types of the most
often planned insulin treatment regimens (CT and BOT) as
well as the form of administration (single-use pen).
According to German diabetes guidelines, the
therapeutic target of diabetes treatment is the improvement
and maintenance of quality of life of older people [5]. Easy
administration of insulin has a positive impact on the
quality of life of the older patient by a low frequency of
daily insulin injections [5]. Human insulin was used more
often than insulin analogs, although improved clinical
profiles of insulin analogs and premixed analog insulins
may be advantageous in older people with diabetes with the
ease of use of newer insulin delivery devices [27, 28].
More than 70 % had cognitive deficiency. Knowing that
approximately 80 % of the participants had a reduced
hearing capacity, the question that arises is whether the
cognitive abilities of many persons were possibly under-
estimated. It was shown that the combination of both dis-
turbances is quite frequent and hearing aids could have
positive effects on cognitive function [29, 30].
Participation in a structured treatment program is asso-
ciated with an improvement in quality of life of older people
with type 2 diabetes [31]. Focusing on the needs of older
persons can improve diabetes control and reduce acute
complications better than standard group education [7]. In
this study, participation in a training program was planned
for the vast majority, including persons with cognitive de-
ficiency. The SGS program was especially developed for
older persons with diabetes, considering the limited re-
sources and learning capabilities of older people. It is done in
groups of four to six persons and provides self-management
skills especially in insulin therapy. It is effective in im-
proving metabolic control and in maintaining independence
in older patients with diabetes [7]. In this study, an adequate
education with adapted programs was definitely under-rep-
resented for the older patient pool [32]. In addition, the im-
portance of diabetes training for relatives was apparently
underestimated. This is of relevance because the diabetes
knowledge of related carers can only be rated insignificantly
higher than that of the older populations [33].
The strength of the study is the high number of patients
reached. with 500 of about 1.150 diabetologic centers
evenly allocated in Germany [14]. Even if we do not know
the reasons for non-attendance, we believe this is a fairly
good result for a survey. A limitation of this study is the
lack of operationalization, as most of the geriatric syn-
dromes were only assigned by the experience of the
treating practitioner. Further research including a compre-
hensive geriatric assessment to quantify the resources and
deficits of this population should be performed. Further-
more, diabetes complications as nephropathy, retinopathy,
and polyneuropathy may be underestimated because of the
protocol of this study. The VEGAS study demonstrates that
further efforts are required to improve the healthcare
situation of older people with diabetes with respect to the
high prevalence of geriatric syndromes and co-morbidity
during de novo insulin treatment.
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